Human Immunology News

Human Immunology News is an online publication and email newsletter for researchers studying the human immune system.

T Cell Senescence and Exhaustion: Molecular Mechanisms and Immune Rejuvenation for Cancer Immunotherapy

September 4, 2026

[Signal Transduction and Targeted Therapy] The authors provide a comprehensive overview of T cell replenishment in homeostasis, followed by the molecular hallmarks and signaling pathways of T cell senescence and exhaustion.

Retinoic Acid-Driven Expansion of CD16hiCD177+ Neutrophils Mediates Steroid-Resistant GI-GVHD

September 4, 2026

[Blood] Through single-cell RNA sequencing of patient blood, researchers identified a specific neutrophil subset that is markedly expanded in steroid-resistant gastrointestinal graft-versus-host disease.

Peripheral Th17 Immune Signature Associates with Excellent Response to Anti-PD-1/Anti-PD-L1 Therapy across Solid Tumors

September 4, 2026

[Cancer Immunology Research] The authors prospectively collected blood samples from 124 patients with advanced and/or metastatic pan-solid tumors treated as standard of care with anti–PD-1 or anti–PD-L1 alone or in combination with other agents. Peripheral immune cells were analyzed by cytometry by time of flight, and cytokines were analyzed using a multiplex immunoassay.

VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer

September 4, 2026

[Cancer Immunology Research] Scientists performed immunohistochemistry, proteomic profiling, and single-cell RNA sequencing on patient samples. These analyses identified a distinct subpopulation of V-domain immunoglobulin suppressor of T cell activation (VISTA)–positive neutrophils enriched in resistant tumors.

Dr. Antoni Ribas Receives ESMO Lifetime Achievement Award for Contributions to Cancer Immunotherapy

September 4, 2026

[UCLA Health] Dr. Antoni Ribas, professor of medicine at the David Geffen School of Medicine at UCLA has received the 2026 ESMO Lifetime Achievement Award for his pioneering contributions to cancer immunotherapy and translational research.

Mepolizumab Modifies Blood Eosinophil Proteome and Transcriptome in Severe Eosinophilic Asthma

September 4, 2026

[Allergy] Researchers characterized the molecular and functional signature of circulating eosinophils in severe eosinophilic asthma in response to mepolizumab therapy. They revealed a downregulation of cytoskeleton-associated proteins and effector-related proteins and genes following mepolizumab treatment.

Mucosal Immunity: Mechanism and Application in Cancer Immunotherapy

September 4, 2026

[Journal of Hematology & Oncology] Mucosal tissues are among the most common sites of tumor initiation, and therefore harnessing mucosal immune to fight against malignant cells represents a feasible option for optimizing and improving current antitumor therapies.

Ikaros Degradation by Mezigdomide Reduces T Cell Dysfunction and Improves the Efficacy of Antimyeloma T Cell Therapies

September 4, 2026

[Blood] Using bone marrow samples from patients with multiple myeloma, researchers demonstrated a significant reduction in dysfunctional T cell populations expressing exhaustion markers, such as TIGIT, upon treatment with mezigdomide.

UNC Researcher Wins Major Grant to Study the Role of Endoplasmic Reticulum in T-Cell Metabolism

September 2, 2026

[UNC School of Medicine] Dr. Jessica Thaxton at the UNC School of Medicine has been awarded a prestigious $700,000 grant from the Mathers Foundation to support research into the role of the endoplasmic reticulum in T cell metabolism and cancer development.

Immune Checkpoints and Immunoregulation in Metabolic Diseases and Cancers: Pathological Mechanisms and Therapeutic Potential

September 2, 2026

[Signal Transduction and Targeted Therapy] Growing research demonstrates that immune checkpoint pathways, particularly the PD-1/PD-L1 axis, play dual roles in immune regulation and metabolic modulation by orchestrating inflammatory responses and energy metabolism.

Interleukin-33 and Its Receptor: Multifaceted Roles and Emerging Therapeutic Potential

September 2, 2026

[Nature Reviews Immunology] Scientists describe the effects of IL-33 in various diseases, including viral infections, cancer, graft-versus-host disease, colitis, autoimmunity, chronic obstructive pulmonary disease, asthma and allergy.

The NLRP3 Inflammasome at the Crossroads of Innate Immune Signaling and Cell Death

September 2, 2026

[Cellular & Molecular Immunology] Substantial crosstalk exists between NLRP3 and other inflammasomes and programmed cell death pathways. The authors summarize recent advances in our understanding of the molecular mechanisms that mediate these interactions, focusing on shared signaling components, organelle dynamics, and posttranslational modifications.

Each issue of Human Immunology News provides up-to-date coverage of the latest news in immunology research performed using human cells or subjects. Our expert editors hand-pick recent research papers and review articles from relevant high-impact peer-reviewed journals on topics including immunotherapy, autoimmunity, adaptive, and innate immunity in humans. We also feature news on clinical trials, award announcements, and funding opportunities.